Literature DB >> 22394540

Cranial and related sensorimotor impairments in rodent models of Parkinson's disease.

Sheila M Fleming1, Tim Schallert, Michelle R Ciucci.   

Abstract

In Parkinson's disease both limb and cranial sensorimotor functions are impaired, leading to a profound diminished quality of life for many patients. Toxin and genetic animal models of Parkinson's disease are likely essential for understanding the pathology associated with these impairments as well as for the development and testing of potential therapeutics. Here we describe useful novel and established behavioral outcome measures for assessing limb and cranial sensorimotor functions in toxin and genetic models of parkinsonism in rats and mice.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22394540     DOI： 10.1016/j.bbr.2012.02.034

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN： 0166-4328            Impact factor:   3.332


  12 in total

1.  Lentiviral-mediated knock-down of GD3 synthase protects against MPTP-induced motor deficits and neurodegeneration.

Authors:  Anandh Dhanushkodi; Yi Xue; Emily E Roguski; Yun Ding; Shannon G Matta; Detlef Heck; Guo-Huang Fan; Michael P McDonald
Journal:  Neurosci Lett       Date:  2018-11-01       Impact factor: 3.046

2.  The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.

Authors:  Tanuja Bordia; Matthew McGregor; Roger L Papke; Michael W Decker; J Michael McIntosh; Maryka Quik
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

3.  Modulation dynamics in the orofacial sensorimotor cortex during motor skill acquisition.

Authors:  Fritzie I Arce-McShane; Nicholas G Hatsopoulos; Jye-Chang Lee; Callum F Ross; Barry J Sessle
Journal:  J Neurosci       Date:  2014-04-23       Impact factor: 6.167

4.  Relationships among rat ultrasonic vocalizations, behavioral measures of striatal dopamine loss, and striatal tyrosine hydroxylase immunoreactivity at acute and chronic time points following unilateral 6-hydroxydopamine-induced dopamine depletion.

Authors:  Laura M Grant; David G Barnett; Emerald J Doll; Glen Leverson; Michelle Ciucci
Journal:  Behav Brain Res       Date:  2015-05-27       Impact factor: 3.332

5.  Changes to Ventilation, Vocalization, and Thermal Nociception in the Pink1-/- Rat Model of Parkinson's Disease.

Authors:  Rebecca A Johnson; Cynthia A Kelm-Nelson; Michelle R Ciucci
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

6.  Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways.

Authors:  S E Gombash; F P Manfredsson; R J Mandel; T J Collier; D L Fischer; C J Kemp; N M Kuhn; S L Wohlgenant; S M Fleming; C E Sortwell
Journal:  Gene Ther       Date:  2014-05-08       Impact factor: 5.250

7.  Early-onset Parkinsonian behaviors in female Pink1-/- rats.

Authors:  Julia M Marquis; Samantha E Lettenberger; Cynthia A Kelm-Nelson
Journal:  Behav Brain Res       Date:  2019-09-19       Impact factor: 3.332

8.  Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.

Authors:  Jason R Cannon; Kindiya D Geghman; Victor Tapias; Thomas Sew; Michelle K Dail; Chenjian Li; J Timothy Greenamyre
Journal:  Exp Neurol       Date:  2012-11-12       Impact factor: 5.330

9.  Behavioural effects of basal ganglia rho-kinase inhibition in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Salim Yalcin Inan; Burak Cem Soner; Ayse Saide Sahin
Journal:  Metab Brain Dis       Date:  2016-03-21       Impact factor: 3.584

10.  Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.

Authors:  Cynthia A Kelm-Nelson; Alexander F L Brauer; Michelle R Ciucci
Journal:  Behav Brain Res       Date:  2016-03-26       Impact factor: 3.332
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.